Applied Biosystems, a division of Life Technologies Corporation (NASDAQ:LIFE), today announced the introduction of a new line of genotyping assays that enable researchers to more closely study the significant role that DNA copy number structural variation plays in human health and disease. The TaqMan® Copy Number Assays are designed to detect and quantify copy number variations (CNVs), which are one of the most frequently occurring forms of structural change within a genome. These assays will enable pharmaceutical, clinical and academic researchers to accurately detect CNVs, which are changes in the number of copies of a gene, a part of a gene, or a large stretch of DNA that occur throughout a genome.

CNVs alter DNA in a way that impacts a host of biological processes. These include the development of cancer, immune system and neurological disorders, as well as how individuals respond to treatments for disease. The TaqMan Copy Number Assays will help researchers to better understand these processes by allowing them to determine CNVs from DNA samples, through a real-time PCR reaction.

An example of this type of research is occurring at Harvard Medical School, Brigham and Women’s Hospital. Researchers there are studying the locations of CNVs in the human genome, and how they can be used as biological markers for susceptibility to human diseases. They are using TaqMan Copy Number Assays to validate the discovery of CNVs identified through the use of array-based platforms.

“Patterns of specific copy number variants have already been associated with increased susceptibility to several human diseases and traits,” said Charles Lee, Ph.D., an Associate Professor in the Department of Pathology at Harvard Medical School, Brigham and Women’s Hospital. “The TaqMan Copy Number Assays represent an excellent complementary technology for confirming the results of our CNV discovery projects, giving us great confidence in the accuracy of our datasets.”

The TaqMan Copy Number Assay solution consists of more than 1.6 million pre-designed TaqMan Copy Number Assays, and Custom TaqMan Copy Number Assays, which allow researchers to detect CNVs in a specific gene, or genome region, if that assay is not available in the pre-designed set. These solutions, in addition to data analysis software, are available on the Applied Biosystems web site.

“Scientists need a powerful genotyping tool that easily validates the discovery of genomic copy number differences in DNA samples,” said Peter Dansky, President of Life Technologies’ Molecular Biology Systems Division. “This technology for advanced genomics research will enable them to perform large-scale screens of biological samples, which will potentially lead to the development of biological markers that will increase their understanding of genetic variation and its role in human disease.”

Applied Biosystems is a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. It is a market leader in providing fast, simple and effective genotyping tools. Applied Biosystems, together, with Invitrogen – a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics – is part of Life Technologies Corporation, which markets the life science industry’s most comprehensive portfolio of solutions for molecular and cell biology. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world.

For more information, please visit: www.appliedbiosystems.com and www.invitrogen.com.

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.

Copyright 2009. Life Technologies Corporation. All rights reserved. AB (Design), and Applied Biosystems are registered trademarks of Life Technologies or its subsidiaries in the United States and/or certain other countries. TaqMan® is a registered trademark of Roche Molecular Systems, Inc.